nach oben

Erschienen in:

2015 | OriginalPaper | Buchkapitel

38. Pankreastumoren

verfasst von : Marcus Bahra, Prof. Dr. med., Florian Lordick, Prof. Dr. med., Manfred P. Lutz, Professor Dr. med., Matthias Glanemann, Prof. Dr. med., Peter Neuhaus, Prof. Dr. med.

Erschienen in: Viszeralmedizin

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Autoren

Gastroenterologie: M. P. Lutz

Onkologie: F. Lordick

Viszeralchirurgie: M. Bahra, M. Glanemann, P. Neuhaus

Adamek HE et al (2000) Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: a prospective controlled study. Lancet 356(9225):190–193CrossRefPubMed

Alexakis N, Halloran C et al (2004) Current standards of surgery for pancreatic cancer. Br J Surg 91(11):1410–1427CrossRefPubMed

Aristu J et al (2003) Surgical resection after preoperative chemoradiotherapy benefits selected patients with unresectable pancreatic cancer. Am J Clin Oncol 26(1):30–36CrossRefPubMed

Azria D et al (2002) Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil and cisplatin. Pancreas 25(4):360–365CrossRefPubMed

Bajetta E et al (1999) Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility study. Int J Radiat Oncol Biol Phys 45(2):285–289CrossRefPubMed

Bartsch DK et al (2004) Prevalence of familial pancreatic cancer in Germany. Int J Cancer 110(6):902–906CrossRefPubMed

Berlin J, Catalano P, Thomas J et al (2002) A phase III study of gemcitabine in combination with 5-FU vs gemcitabine alone in patients with advanced pancreatic carcinoma (E2297): an Eastern Cooperative Oncology Group (ECOG) trial. J Clin Oncol 20:3270–3275CrossRefPubMed

Bronstein YL et al (2004) Detection of small pancreatic tumors with multiphasic helical CT. Am J Roentgenol 182(3):619–623CrossRef

Brugge WR (2008) The incidental pancreatic cyst on abdominal computerizes tomography imaging: diagnosis and management. Clin Gastroenterol Hepatol 6:140–144CrossRefPubMed

Brunner TB et al (2000) Preoperative chemoradiation in locally advanced pancreatic carcinoma: a phase II study. Onkologie 23(5):436–442CrossRefPubMed

Burris HA, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413PubMed

Carpelan-Holmstrom M et al (2002) CEA, CA 19–9 and CA 72–4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res 22(4):2311–2316PubMed

Chauffert B, Mornex F, Bonnetain F et al (2008) Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. Ann Oncol 19(9):1592–1599CrossRefPubMed

Cleary SP et al (2004) Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg 198(5):722–731CrossRefPubMed

Coleman RE (1998) Clinical PET in oncology. Clin Positron Imaging 1(1):15–30CrossRefPubMed

Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. N Engl J Med 364:1817–1825CrossRefPubMed

Crane C et al (2001) Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Gastrointest Cancer 29(1):9–18CrossRefPubMed

Ducreux M, Rougier P, Pignon J-P et al (2002) A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol 13:1185–1191CrossRefPubMed

Ekbom A et al (1994) Pancreatitis and pancreatic cancer: a population-based study. J Natl Cancer Inst 86(8):625–627CrossRefPubMed

England RE, Martin DF (1996) Endoscopic and percutaneous intervention in malignant obstructive jaundice. Cardiovasc Intervent Radiol 19(6):381–387CrossRefPubMed

Eskelinen MHU (2002) Serological tumor markers in pancreatic cancer. In: Diamandis EPFH, Lilja H, Chan DW, Schwartz MK (Hrsg) Tumor markers-physiology pathobiology, technology, and clinical applications. AACC Press, Washington DC, S 265–269

Everhart J, Wright D (1995) Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis JAMA 273(20):1605–1609PubMed

Fuchs CS et al (1996) A prospective study of cigarette smoking and the risk of pancreatic cancer. Arch Intern Med 156(19):2255–2260CrossRefPubMed

Gaa J et al (2001) Diagnosis of pancreas tumors: MRI or multidetector spiral CT? Kongressbd Dtsch Ges Chir Kongr 118:73–77PubMed

Geer RJ, Brennan MF (1993) Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 165(1):68–72 (discussion 72–73)CrossRefPubMed

Giardiello FM et al (2000) Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 119(6):1447–1453CrossRefPubMed

Gillen S, Schuster T, Meyer zum Buschenfelde C et al (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. Plos 7 e1000267

Glimelius B, Hoffman K, Sjoden PO et al (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7:593–600CrossRefPubMed

Hahn SA et al (2003) BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 95(3):214–221CrossRefPubMed

Hammel PR et al (2000) Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d‘Etude de la Maladie de von Hippel-Lindau. Gastroenterology 119(4):1087–1095CrossRefPubMed

Hecht F, Hecht BK (1990) Cancer in ataxia-telangiectasia patients. Cancer Genet Cytogenet 46(1):9–19CrossRefPubMed

Hoffman JP et al (1995) A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. Am J Surg 169(1):71–77 (discussion 77–78)CrossRefPubMed

Howe GR, Jain M, Miller AB (1990) Dietary factors and risk of pancreatic cancer: results of a Canadian population-based case-control study. Int J Cancer 45(4):604–608CrossRefPubMed

Howe GR et al (1991) Cigarette smoking and cancer of the pancreas: evidence from a population-based case-control study in Toronto, Canada. Int J Cancer 47(3):323–328CrossRefPubMed

Hruban RH et al (1993) K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 143(2):545–554PubMedCentralPubMed

Hruban RH et al (2004) An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 28(8):977–987CrossRefPubMed

Huang QJ et al (2002) Spiral multi-phase CT in evaluating resectability of pancreatic carcinoma. Hepatobiliary Pancreat Dis Int 1(4):614–619PubMed

Hunt GC, Faigel DO (2002) Assessment of EUS for diagnosing, staging, and determining resectability of pancreatic cancer: a review. Gastrointest Endosc 55(2):232–237CrossRefPubMed

Jessup JM et al (1993) Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. Arch Surg 128(5):559–564CrossRefPubMed

Jiang JT et al (2004) Serum level of TSGF, CA242 and CA19–9 in pancreatic cancer. World J Gastroenterol 10(11):1675–1677PubMed

Kalser MH, Ellenberg SS (1985) Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120(8):899–903CrossRefPubMed

Karlson BM et al (1999) Abdominal US for diagnosis of pancreatic tumor: prospective cohort analysis. Radiology 213(1):107–111CrossRefPubMed

Kleeff J, Reiser C et al (2007) Surgery for recurrent pancreatic ductal adenocarcinoma. Ann Surg 245(4):566–572PubMedCentralCrossRefPubMed

Klinkenbijl JH et al (1999) Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230(6):776–782 (discussion 782–784)PubMedCentralCrossRefPubMed

Kornek GV et al (2000) Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin. Br J Cancer 82(1):98–103PubMedCentralCrossRefPubMed

La Vecchia C et al (1990) Medical history, diet and pancreatic cancer. Oncology 47(6):463–466CrossRefPubMed

Laurent-Puig P et al (1995) Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases. Gut 36(3):455–458PubMedCentralCrossRefPubMed

Lemke AJ et al (2004) Retrospective digital image fusion of multidetector CT and 18 F-FDG PET: clinical value in pancreatic lesions – a prospective study with 104 patients. J Nucl Med 45(8):1279–1286PubMed

Li CP et al (2003) Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys 57(1):98–104CrossRefPubMed

Loehrer PJ, Feng Y, Cardenes H et al (2011) Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 29:4105–4112PubMedCentralCrossRefPubMed

Lopez Hanninen E et al (2002) Prospective evaluation of pancreatic tumors: accuracy of MR imaging with MR cholangiopancreatography and MR angiography. Radiology 224(1):34–41CrossRefPubMed

Louhimo J et al (2004) Serum HCG beta and CA 72–4 are stronger prognostic factors than CEA, CA 19–9 and CA 242 in pancreatic cancer. Oncology 66(2):126–131CrossRefPubMed

Lowenfels AB et al (1993) Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 328(20):1433–1437CrossRefPubMed

Lynch HT, Fusaro RM (1991) Pancreatic cancer and the familial atypical multiple mole melanoma (FAMMM) syndrome. Pancreas 6(2):127–131CrossRefPubMed

Maringhini A et al (1993) Clinical presentation and ultrasonography in the diagnosis of pancreatic cancer. Pancreas 8(2):146–150CrossRefPubMed

Meyers MO et al (2004) Is reporting of recurrence data important in pancreatic cancer? Ann Surg Oncol 11(3):304–309CrossRefPubMed

Michaud DS et al (2003) Dietary meat, dairy products, fat, and cholesterol and pancreatic cancer risk in a prospective study. Am J Epidemiol 157(12):1115–1125CrossRefPubMed

Millikan KW et al (1999) Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg 65(7):618–623 (discussion 623–624)PubMed

Mittal A et al (2004) Matched study of three methods for palliation of malignant pyloroduodenal obstruction. Br J Surg 91(2):205–209CrossRefPubMed

Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25(15):1960–1966CrossRefPubMed

Mulcahy HE et al (1998) A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin Cancer Res 4(2):271–275PubMed

Neoptolemos JP, Stocken DD, Friess H et al (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200–1210CrossRefPubMed

Neoptolemos JP, Stocken DD, Bassi C et al (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304(10):1073–1081CrossRefPubMed

Niedergethmann M, Grützmann R et al (2008) Outcome of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas (IPMN): a 10-year experience. World J Surg 32(10):2253–2260CrossRefPubMed

Norell SE et al (1986) Diet and pancreatic cancer: a case-control study. Am J Epidemiol 124(6):894–902PubMed

Oettle H, Post S, Neuhaus P (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer a randomized controlled trial. JAMA 297:267–277CrossRefPubMed

Ojajarvi IA et al (2000) Occupational exposures and pancreatic cancer: a meta-analysis. Occup Environ Med 57(5):316–324PubMedCentralCrossRefPubMed

Ozkan H, Kaya M, Cengiz A (2003) Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer. Hepatogastroenterology 50(53):1669–1674PubMed

Palesty JA, Dudrick SJ (2003) What we have learned about cachexia in gastrointestinal cancer. Dig Dis 21(3):198–213CrossRefPubMed

Palmer KR, Kerr M, Knowles G, Cull A, Carter DC, Leonard RC (1994) Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 81:882–885CrossRefPubMed

Pederzoli P (1998) Phase 3 Trial of SMS 201–995 pa LAR (SMS pa LAR) vs placebo in unresectable stage II, III and IV pancreatic cancer. In: ASCO Annual Meeting

Pedrazzoli S, DiCarlo V et al (1998) Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 228(4):508–517PubMedCentralCrossRefPubMed

Phillips AR et al (2002) Ethnic disparity of pancreatic cancer in New Zealand. Int J Gastrointest Cancer 31(1–3):137–145CrossRefPubMed

Pisters PW et al (2001) Effect of preoperative biliary decompression on pancreaticoduodenectomy-associated morbidity in 300 consecutive patients. Ann Surg 234(1):47–55PubMedCentralCrossRefPubMed

Povoski SP et al (1999) Preoperative biliary drainage: impact on intraoperative bile cultures and infectious morbidity and mortality after pancreaticoduodenectomy. J Gastrointest Surg 3(5):496–505CrossRefPubMed

Prott FJ et al (1997) Combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the pancreas: results of a feasibility study. Br J Cancer 75(4):597–601PubMedCentralCrossRefPubMed

Ren YX et al (2004) Detection of point mutation in K-ras oncogene at codon 12 in pancreatic diseases. World J Gastroenterol 10(6):881–884PubMed

Reni M, Panucci MG, Passoni P et al (2004) Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial. Cancer Invest 22:688–696CrossRefPubMed

Rich T et al (2004) Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98–12. Am J Clin Oncol 27(1):51–56CrossRefPubMed

Richards DA, Kindler HL, Oettle H et al (2004) A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas. Proc Am Soc Clin Oncol 23:A4.007

Ries LA et al (2000) The annual report to the nation on the status of cancer, 1973–1997, with a special section on colorectal cancer. Cancer 88(10):2398–2424CrossRefPubMed

Risch HA (2003) Etiology of pancreatic cancer, with a hypothesis concerning the role of N-nitroso compounds and excess gastric acidity. J Natl Cancer Inst 95(13):948–960CrossRefPubMed

Sakorafas GH, Smyrniotis V, Reid-Lombardo KM, Sarr MG (2011) Primary pancreatic cystic neoplasms revisited: Part II Mucinous cystic neoplasms. Surg Oncol 20(2):e93–101CrossRefPubMed

Santo E (2004) Pancreatic cancer imaging: which method? Jop 5(4):253–257PubMed

Schima W et al (2002) Diagnosis and staging of pancreatic cancer: comparison of mangafodipir trisodium-enhanced MR imaging and contrast-enhanced helical hydro-CT. Am J Roentgenol 179(3):717–724CrossRef

Seufferlein T, Bachet LB, Van Cutsem E, Rougier P (2012) Pancreatic adenocarcinoma: ESMO–ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):vi33–vi40CrossRef

Shinchi H et al (2002) Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 53(1):146–150CrossRefPubMed

Silverman DT et al (1994) Cigarette smoking and pancreas cancer: a case-control study based on direct interviews. J Natl Cancer Inst 86(20):1510–1516CrossRefPubMed

Slesak B et al (2004) TPS and CA 19-9 measurements in the follow-up of patients with pancreatic cancer and chronic pancreatitis. Int J Biol Markers 19(2):115–119PubMed

Snady H et al (2000) Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 89(2):314–327CrossRefPubMed

Sohn TA et al (2000) Do preoperative biliary stents increase postpancreaticoduodenectomy complications? J Gastrointest Surg 4(3):258–267 (discussion 267–268)CrossRefPubMed

Swift M, Chase CL, Morrell D (1990) Cancer predisposition of ataxia-telangiectasia heterozygotes. Cancer Genet Cytogenet 46(1):21–27CrossRefPubMed

Varghese JC et al (1999) Role of MR cholangiopancreatography in patients with failed or inadequate ERCP. Am J Roentgenol 173(6):1527–1533CrossRef

Vyas S, Markar S, Ezzat TM, Ajit A (2011) Cystic lesions of the pancreas: current trends in approach and management. Postgrad Med J 87:207–214CrossRefPubMed

Werner JB, Bartosch-Härlid A, Andersson R (2011) Cystic pancreatic lesions: Current evidence for diagnosis and treatment. Scan J Gastroenterol 46(7–8):773–788CrossRef

Wilkowski R et al (2004) Concurrent chemoradiotherapy with gemcitabine and cisplatin after incomplete (R1) resection of locally advanced pancreatic carcinoma. Int J Radiat Oncol Biol Phys 58(3):768–772CrossRefPubMed

Titel: Pankreastumoren
verfasst von: Marcus Bahra, Prof. Dr. med.
Florian Lordick, Prof. Dr. med.
Manfred P. Lutz, Professor Dr. med.
Matthias Glanemann, Prof. Dr. med.
Peter Neuhaus, Prof. Dr. med.
Verlag: Springer Berlin Heidelberg
Buch: Viszeralmedizin
Print ISBN: 978-3-642-14300-7

Electronic ISBN: 978-3-642-14301-4

Copyright-Jahr: 2015
DOI: https://doi.org/10.1007/978-3-642-14301-4_38

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

38. Pankreastumoren

Zusammenfassung

Autoren

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Zusammenfassung

Autoren

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin